{"page_content": " 241 Based on the most recent data from our independent compensation consultant.\nALKERMES \u2022  CORPORATE RESPONSIBILITY REPORT \u2022 SOCIALEmployee Data\nWe have more than 2,000 employees across the U.S. and \nIreland who are key to our ability to develop, manufacture and \nadvance treatment options for patients and who contribute to \nour culture of passion, dedication and excitement for the work \nthat we do. Our 2020 voluntary attrition rate of 9.6% was \nbelow the industry benchmark of 10.5%.1 We also conduct \nannual reviews to assess performance and leadership \npotential and to help inform our retention strategies and \nsuccession planning for key roles.\nTotal Employees as of Year-End 2020 \u2013 2,235\nBy Location\nIreland Athlone 330\nDublin 42\nU.S. Massachusetts 782\nOhio 522\nU.S. Field-based 559\nBy Full time / part time\nIreland 365 full time / 7 part time  \nU.S. 1,858 full time / 5 part time\nGender Diversity and Pay Ratio\nAs of year-end 2020, Alkermes\u2019 workforce was 47% female \nand 53% male, and our ratio of female to male employees \nwas aligned with industry peers across all levels.1 \nAs of year-end 2020, median compensation for males and \nfemales at Alkermes was substantially equal across metrics  \nof base salary, total cash compensation and total \ncompensation including equity. The average salary of our \nfemale employees as compared to that of our male employees \nwas also aligned with industry averages. Minimizing gender \npay disparities has been a priority for Alkermes, and we \nmonitor our pay practices and make focused adjustments \nto maintain equitable pay across our employee population. \nAdditionally we continuously review and adapt our recruiting \nand employment offer processes to be compliant with U.S. \nfederal and state and Irish laws. We make offers to candidates \nbased on candidates\u2019 experience and skills in comparison \nto our current employees, and without regard to their \ncompensation from previous employers. \n Employees as of Year-End 2020\nBy Gender By Level\nMale1,177\n231 Ireland\n946 U.S.Entry level 46% female / 54% male\nMid-level 49% female / 51% male\nFemale1,058\n141 Ireland\n917 U.S.Senior level 40% female / 60% male\nExecutive level 20% female / 80% male\nSupporting Diversity in Leadership \nDeveloping a diverse leadership team is an important \nelement of our success and we are proud to support and \ninvest in diversity at all levels of the organization, including in \nleadership roles. \nWe have made substantial progress in the area of gender \ndiversity in the last four years, with significant gains in the \npercentages of women in senior roles, including an increase \nin the percentage of female employees on our management \nteam from 14% in 2017 to 23% in 2021. \nWe provide a variety of leadership development opportunities, \nincluding those offered through Women Unlimited, Inc. (WUI), \nan organization that runs programs for female leaders at \nvarious stages of their careers. Over the last five years, 100 \nfemale leaders across the organization have participated in \nWUI programs, including: \n\u2022 IMpower: A six-month program for high potential, early- \n career or emerging female talent; \n\u2022 LEAD: A one-year program for mid-level managers with  \n a focus on personal brand, mentoring and on-the job action  \n assignments; and\n\u2022 FEW:  A one-year program for senior level executives with  \n a focus on executive skills assessment and best practices  \n across industries.\nWe are a proud corporate partner of the Healthcare \nBusinesswomen\u2019s Association and support its core purpose \nof furthering the advancement and impact of women in the \nbusiness of healthcare.\nIn 2020, the Company also sponsored employee \nmemberships for Conexi\u00f3n, an organization dedicated to the \ndevelopment of Hispanic-Latino leaders, and Chief, a private \nmembership network focused on connecting and supporting \nwomen executive leaders.", "metadata": {"source": "NASDAQ_ALKS_2021.pdf", "page": 23, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}